Treatment Approach for Persistent Asthma with Elevated Eosinophils Uncontrolled on ICS
Add a long-acting beta-agonist (LABA) to your current inhaled corticosteroid regimen as the preferred next step for adults with persistent asthma and elevated eosinophils who remain uncontrolled on ICS alone. 1
Stepwise Treatment Algorithm
Step 1: Optimize Current ICS Therapy
Before escalating treatment, verify:
- Inhaler technique is correct - improper technique is a common cause of apparent treatment failure
- Medication adherence - confirm the patient is actually taking the ICS consistently
- Environmental triggers - identify and address allergens, irritants, or occupational exposures contributing to poor control 2
Step 2: Add LABA to Low-to-Medium Dose ICS (Preferred)
For patients ≥12 years with moderate persistent asthma uncontrolled on ICS alone:
- Combination ICS/LABA is the preferred treatment over increasing ICS dose alone 1
- This approach provides superior symptom control and exacerbation reduction compared to doubling ICS dose 2
- Never use LABA as monotherapy - LABAs without ICS increase severe exacerbations and mortality risk 1
Step 3: Alternative Options (If LABA Not Suitable)
If LABA cannot be used or is insufficient:
- Increase ICS to medium-to-high dose 1
- Add leukotriene receptor antagonist (LTRA) - montelukast or zafirlukast 1, 3
- LTRAs are less effective than adding LABA but offer once-daily dosing and high compliance
- Can be combined with ICS/LABA if needed
Step 4: Role of Eosinophil Count in Treatment Decisions
Elevated eosinophils (≥300 cells/μL) predict better response to corticosteroids 3:
- Non-invasive measurement of airway inflammation has clinical utility 3
- Eosinophilic inflammation indicates type-2 asthma, which responds well to ICS-based therapy
- Consider measuring fractional exhaled nitric oxide (FeNO) as additional type-2 inflammation marker 3
Step 5: When to Consider Biologic Therapy
If asthma remains uncontrolled on high-dose ICS/LABA combination:
- Consult asthma specialist for severe persistent asthma 2
- Consider biologic therapy for severe eosinophilic asthma:
- Anti-IL-5 therapy (mepolizumab, reslizumab, benralizumab) for eosinophil counts ≥150-300 cells/μL 4, 5
- Dupilumab (anti-IL-4 receptor) for type-2 inflammation with eosinophils ≥150 cells/μL or FeNO ≥20 ppb 6, 7, 8
- Dupilumab reduced exacerbations by 87% in patients with elevated eosinophils uncontrolled on ICS/LABA 6
Critical Pitfalls to Avoid
Do not prescribe SABA alone - all adults and adolescents with asthma require ICS-containing medication 9. Using SABA more than 2 days/week (excluding exercise prophylaxis) indicates inadequate control requiring intensified anti-inflammatory therapy 1.
Recognize eosinophil variability - a single eosinophil count may not reflect disease activity. Eosinophil variability ≥50% better predicts hospital episodes than absolute values 10. Consider serial measurements before making treatment decisions.
Address comorbidities - chronic rhinosinusitis with nasal polyps occurs in 50% of eosinophilic asthma cases 5. Treat these conditions as they contribute to poor asthma control.
Monitoring Response
Assess control at each visit using:
- Symptom frequency - daytime symptoms, nighttime awakenings, activity limitation
- SABA use - increased use signals worsening control
- Lung function - pre-bronchodilator FEV1 and peak expiratory flow
- Exacerbation history - frequency requiring oral corticosteroids or hospitalization 1
For acute exacerbations, use oral corticosteroids: 40-60 mg prednisone daily for 5-10 days in adults. Tapering is unnecessary 1.